(Q27853339)

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Esra A Akbay

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Leena Gandhi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Hajime Asahina

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sidhu Gangadharan

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Daniel B Costa

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Kwok Kin Wong

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

23

F Stephen Hodi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

21

Gordon J Freeman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Yvonne Y Li

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Grit S Herter-Sprie

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Kevin A Buczkowski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

William G Richards

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Amanda J Redig

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Scott J Rodig

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Robert E Jones

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Meghana M Kulkarni

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Mari Kuraguchi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sangeetha Palakurthi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Peter E Fecci

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Bruce E Johnson

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jeffrey A Engelman

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Raphael Bueno

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Glenn Dranoff

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Pasi A Janne

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Peter S Hammerman

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

17 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

published in

Nature Communications

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

10501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

8 March 2020

copyright license

start time

17 February 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

describes a project that uses

limma

1 reference

22 June 2022

https://europepmc.org/article/PMC/4757784

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

The blockade of immune checkpoints in cancer immunotherapy

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

PD-1 and its ligands in tolerance and immunity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Pembrolizumab for the treatment of non-small-cell lung cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

limma powers differential expression analyses for RNA-sequencing and microarray studies

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

PD-1 blockade induces responses by inhibiting adaptive immune resistance

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Tim-3: an emerging target in the cancer immunotherapy landscape

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Immune modulation in cancer with antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

The impact of genomic changes on treatment of lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Emerging Tim-3 functions in antimicrobial and tumor immunity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4757784

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies

29 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNCOMMS10501

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNCOMMS10501

21 January 2018

Identifiers

DOI

10.1038/NCOMMS10501

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

8 March 2020

ADS bibcode

2016NatCo...710501K

0 references

1023222368

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PubMed publication ID

26883990

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883990%20AND%20SRC:MED&resulttype=core&format=json